| ILY重组蛋白增强利妥昔单抗杀伤骨髓瘤ARH-77细胞的实验研究 |
| |
| 引用本文： | 尤涛,徐勇,余玲. ILY重组蛋白增强利妥昔单抗杀伤骨髓瘤ARH-77细胞的实验研究[J]. 广东药学院学报, 2011, 27(6): 633-636. DOI: 10.3969/j.issn.1006-8783.2011.06.020 |
| |
| 作者姓名： | 尤涛 徐勇 余玲 |
| |
| 作者单位： | 武汉大学人民医院 骨科,湖北 武汉,430060 |
| |
| 基金项目： | 国家留学基金委"建设高水平大学公派留学生项目" |
| |
| 摘 要： | 目的 通过体外实验观察CD59抑制物ILY重组蛋白增强利妥昔单抗(Rituximab)对多发性骨髓瘤ARH-77细胞的补体依赖性细胞毒性效应(CDC效应),探讨联合应用该蛋白治疗多发性骨髓瘤的可行性.方法 FACS分析法侦测ARH-77细胞系的CD20和CD59抗原表达.Alarma blue及Typan blue...
|
| 关 键 词： | ILY重组蛋白 补体依赖性细胞毒性效应 利妥昔单抗 多发性骨髓瘤ARH-77细胞 |
Application of ILY recombinant protein in Rituximab to treat myeloma cells |
| |
| YOU Tao,XU Yong,YU ling. Application of ILY recombinant protein in Rituximab to treat myeloma cells[J]. Academic Journal of Guangdong College of Pharmacy, 2011, 27(6): 633-636. DOI: 10.3969/j.issn.1006-8783.2011.06.020 |
| |
| Authors: | YOU Tao XU Yong YU ling |
| |
| Affiliation: | (Orthopedics Department,Renming Hospital of Wu Han University,Wuhan 430060,China) |
| |
| Abstract: | Objective Through observing the CDC effect of CD59 inhibitor ILY recombinant protein in Rituximab to treat multiple myeloma（MM）ARH-77 cells,we investigate the feasibility of combination with ILY recombinant protein in MM therapy.Methods The expression of CD20 and CD59 in ARH-77 cells was analyzed by FACS.Cells death percentages were measured by alarma blue and typan blue in ARH-77 cells treated with ILY recombinant protein and Rituximab..Results High levels of CD20 and CD59 were detected on the surface of ARH-77 cells.ILY recombinant protein effectively enhanced CDC effect and reversed drug resistance mediated by Rituximab in MM cells.Conclusion The ILY recombinant protein significantly improves Rituximab effect in MM cells therapy,and may be a good adjunctive drug in monoclonal antibodies treatment with tumors. |
| |
| Keywords: | ILY recombinant protein CDC Rituximab multiple myeloma ARH-77cells. |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
